Dominique Thabut

Summary

Country: France

Publications

  1. ncbi Non-invasive diagnosis of large oesophageal varices with FibroTest in patients with cirrhosis: a preliminary retrospective study
    Dominique Thabut
    Hepatogastroenterology Unit, Pitie Salpetriere Hospital, 47 bd de l Hopital, 75013 Paris, France
    Liver Int 26:271-8. 2006
  2. doi Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies
    Thierry Poynard
    University Pierre and Marie Curie Liver Center, Paris, France
    Antivir Ther 15:617-31. 2010
  3. ncbi Management of acute bleeding from portal hypertension
    Dominique Thabut
    Service d Hepatogastroenterologie, Hopital de la Pitie Salpetriere, 75013 Paris, France
    Best Pract Res Clin Gastroenterol 21:19-29. 2007
  4. ncbi Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis B
    Dominique Thabut
    Hepato Gastroenterology Unit, Hopital Pitie Salpetriere, Paris, France
    Eur J Gastroenterol Hepatol 16:1367-73. 2004
  5. ncbi Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure
    Dominique Thabut
    AP HP Service d Hépato Gastroentérologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Hepatology 46:1872-82. 2007
  6. ncbi High-density lipoprotein administration attenuates liver proinflammatory response, restores liver endothelial nitric oxide synthase activity, and lowers portal pressure in cirrhotic rats
    Dominique Thabut
    INSERM, U773, Centre de Recherche Biomedicale Bichat Beaujon CRB3, Paris 75018, France
    Hepatology 46:1893-906. 2007
  7. pmc Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease
    Vlad Ratziu
    Hepato Gastroenterology, AP HP Groupe Hospitalier Pitié Salpétrière, Paris, France
    BMC Gastroenterol 6:6. 2006
  8. ncbi A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C
    Yen Ngo
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, CNRS, Paris, France
    Clin Chem 52:1887-96. 2006
  9. pmc Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease
    Thierry Poynard
    Hepato Gastroenterology, AP HP Groupe Hospitalier Pitié Salpétrière, Paris, France
    BMC Gastroenterol 6:34. 2006
  10. ncbi Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?
    Dominique Thabut
    Services d Hépato gastroentérologie, Group Hospitalier Pitié Salpêtrièe, Paris, France
    Am J Gastroenterol 101:1260-7. 2006

Detail Information

Publications77

  1. ncbi Non-invasive diagnosis of large oesophageal varices with FibroTest in patients with cirrhosis: a preliminary retrospective study
    Dominique Thabut
    Hepatogastroenterology Unit, Pitie Salpetriere Hospital, 47 bd de l Hopital, 75013 Paris, France
    Liver Int 26:271-8. 2006
    ..As portal hypertension is related to liver fibrosis, this study aimed to assess the predictive value of FibroTest, a non-invasive marker of liver fibrosis, for the diagnosis of LOV in cirrhotic patients...
  2. doi Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies
    Thierry Poynard
    University Pierre and Marie Curie Liver Center, Paris, France
    Antivir Ther 15:617-31. 2010
    ..We aimed to review evidence-based published data of biomarkers that have been validated as non-invasive alternatives to biopsy as end points for HBV and HCV infection trials...
  3. ncbi Management of acute bleeding from portal hypertension
    Dominique Thabut
    Service d Hepatogastroenterologie, Hopital de la Pitie Salpetriere, 75013 Paris, France
    Best Pract Res Clin Gastroenterol 21:19-29. 2007
    ....
  4. ncbi Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis B
    Dominique Thabut
    Hepato Gastroenterology Unit, Hopital Pitie Salpetriere, Paris, France
    Eur J Gastroenterol Hepatol 16:1367-73. 2004
    ..The clinical features, course and viral mutations associated with the emergence of viral resistance in this population have not been well studied...
  5. ncbi Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure
    Dominique Thabut
    AP HP Service d Hépato Gastroentérologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Hepatology 46:1872-82. 2007
    ..001). In multivariate analysis, only model for end-stage liver disease score and presence of SIRS, but not infection, remained associated with a poor outcome...
  6. ncbi High-density lipoprotein administration attenuates liver proinflammatory response, restores liver endothelial nitric oxide synthase activity, and lowers portal pressure in cirrhotic rats
    Dominique Thabut
    INSERM, U773, Centre de Recherche Biomedicale Bichat Beaujon CRB3, Paris 75018, France
    Hepatology 46:1893-906. 2007
    ..rHDL administration decreased hepatic TNFalpha, LBP, iNOS, and caveolin-1 expression, restored hepatic eNOS and Akt activity, and significantly lowered the portal pressure and intrahepatic vascular resistance...
  7. pmc Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease
    Vlad Ratziu
    Hepato Gastroenterology, AP HP Groupe Hospitalier Pitié Salpétrière, Paris, France
    BMC Gastroenterol 6:6. 2006
    ..The aim of this study was to determine the diagnostic utility of non-invasive markers of fibrosis, validated in chronic viral hepatitis and alcoholic liver disease (FibroTest, FT), in patients with NAFLD...
  8. ncbi A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C
    Yen Ngo
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, CNRS, Paris, France
    Clin Chem 52:1887-96. 2006
    ..We compared the 5-year prognostic value of the FibroTest with biopsy staging for predicting cirrhosis decompensation and survival in patients with chronic HCV infection...
  9. pmc Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease
    Thierry Poynard
    Hepato Gastroenterology, AP HP Groupe Hospitalier Pitié Salpétrière, Paris, France
    BMC Gastroenterol 6:34. 2006
    ..The aim was to develop and validate a new biomarker of non alcoholic steato hepatitis (NASH) the NashTest (NT) in patients with NAFLD...
  10. ncbi Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?
    Dominique Thabut
    Services d Hépato gastroentérologie, Group Hospitalier Pitié Salpêtrièe, Paris, France
    Am J Gastroenterol 101:1260-7. 2006
    ....
  11. doi The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption
    Francoise Imbert-Bismut
    Department of Biochemistry, APHP Groupe Hospitalier Pitié Salpétrière, Paris, France
    Eur J Gastroenterol Hepatol 21:18-27. 2009
    ..The aim was to improve the accuracy of the percentage of CDT by taking into account the presence of fibrosis and steatosis, estimated using biomarkers FibroTest and SteatoTest...
  12. ncbi Biomarkers of liver fibrosis
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, CNRS ESA 8067 Paris, France
    Adv Clin Chem 46:131-60. 2008
    ..Neither biomarkers nor biopsy are sufficient alone to take definitive decision in a given patient and all the clinical and biological data must be taken into account...
  13. pmc Meta-analyses of FibroTest diagnostic value in chronic liver disease
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, CNRS ESA 8067 Paris, France
    BMC Gastroenterol 7:40. 2007
    ....
  14. pmc Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers
    Thierry Poynard
    APHP Groupe Hospitalier Pitié Salpétrière, Universite Paris VI, CNRS UMR, Paris, France
    PLoS ONE 3:e3857. 2008
    ..The aim was to identify factors associated with LSM accuracy using FT as a non-invasive endpoint and vice versa...
  15. doi Possible mechanisms involved in the discrepancy of hepatic and aortic endothelial nitric oxide synthases during the development of cirrhosis in rats
    Morvarid Shir Mohammadi
    INSERM, U773, Centre de Recherche Biomédical Bichat Beaujon, Hopital Beaujon, Clichy, France
    Liver Int 29:692-700. 2009
    ..The aim of this study was to evaluate the regulation of eNOS and its major modulators in the liver and aorta during the development of cirrhosis in rats...
  16. pmc An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load
    Yen Ngo
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, CNRS UMR 8149, Paris, France
    PLoS ONE 3:e2573. 2008
    ..We compared the 4-year prognostic value of combining FT-AT and viral load for a better definition of the inactive carrier status...
  17. ncbi Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, Paris, France
    Clin Chem 50:1344-55. 2004
    ....
  18. ncbi Natural history and predictors of disease severity in chronic hepatitis C
    Julien Massard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, 47 Boulevard de l Hopital, 75651 Paris Cedex 13, France
    J Hepatol 44:S19-24. 2006
    ..The recent validation of non-invasive biomarkers should facilitate the study of fibrosis progression in large populations...
  19. doi Ex vivo effects of high-density lipoprotein exposure on the lipopolysaccharide-induced inflammatory response in patients with severe cirrhosis
    Arnaud Galbois
    INSERM, U773, Centre de Recherche Biomedicale Bichat Beaujon CRB3, Hopital Beaujon, Clichy, France
    Hepatology 49:175-84. 2009
    ..LPS-induced down-regulation of scavenger receptor, class B, type I (SR-BI) expression was abolished in cirrhotic monocytes...
  20. pmc Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C
    Thierry Poynard
    Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    Comp Hepatol 3:8. 2004
    ..In clinical practice, liver biopsy should be recommended only as a second line test, i.e., in case of high risk of error of biochemical tests...
  21. pmc Assessment of liver fibrosis: noninvasive means
    Thierry Poynard
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, CNRS ESA 8149 Paris, France
    Saudi J Gastroenterol 14:163-73. 2008
    ..There is no evidence based data justifying biopsy as a first line estimate of liver fibrosis. Health authorities in some countries have already approved validated biomarkers as the first line procedure for the staging of liver fibrosis...
  22. pmc Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis
    Marika Rudler
    Assistance Publique Hopitaux de Paris, University Pierre et Marie Curie, Paris, France
    PLoS ONE 10:e0134302. 2015
    ..The aim was to validate the AshTest accuracy in the specific context of use of patients with suspected severe ASH, in order to reduce the need for transjugular biopsy before deciding treatment...
  23. ncbi Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure
    Vincent Di Martino
    Service d Hepato Gastroenterologie, GH Pitié Salpétrière, Paris, France
    Hepatology 40:1426-33. 2004
    ..Pregnancies may have a beneficial impact on the long-term progression of liver fibrosis...
  24. doi Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®)
    Thierry Poynard
    Assistance Publique Hopitaux de Paris AP HP, Groupe Hospitalier Pitie Salpetriere, Paris, France University Pierre et Marie Curie UPMC University of Paris VI, Paris, France INSERM, UMRS 938, Paris, France Electronic address
    J Hepatol 61:994-1003. 2014
    ..The second aim was to validate a previous definition of an inactive carrier based on normal FT and ActiTest® (normal-FT-AT). The third aim was to assess the long-term dynamics of fibrosis in patients with sustained virological response...
  25. pmc The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis
    Thierry Poynard
    Department of Hepato Gastroenterology, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Comp Hepatol 4:10. 2005
    ..Steatosis was blindly assessed by using a previously validated scoring system...
  26. doi Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?"
    Hugo Perazzo
    Hepatology Department, Hopital Pitie Salpetriere, Assistance Publique Hopitaux de Paris, 47 83, Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Clin Res Hepatol Gastroenterol 38:432-9. 2014
    ..We assess the impact of two limitations, the variability of the upper limit of normal for aspartate aminotransferase (AST-ULN) and the risk of overestimating fibrosis stage due to necroinflammatory activity...
  27. doi Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis
    Didier Lebrec
    INSERM, Unité 773, Centre de Recherche Biomédicle Bichat Beaujon CRB3, Paris, France and Service d Hépatologie, Hopital Beaujon, Clichy, France
    Gastroenterology 138:1755-62. 2010
    ..We performed a randomized, placebo-controlled, double-blind trial of its effects in patients with cirrhosis...
  28. doi Rate of employment after liver transplantation in France: a single-centre study
    Marika Rudler
    Departments of aHepatogastroenterology bLiver Transplantation and Hepatobiliary Surgery cAnaesthesiology, La Pitie Salpetriere Hospital, University Pierre and Marie Curie, Paris, France
    Eur J Gastroenterol Hepatol 28:159-63. 2016
    ..A recent study in the USA has shown a very high rate of unemployment after LT (75%). To date, there are no available data in France, where the public health insurance programme guarantees financial protection for everyone...
  29. doi Multicenter prospective validation of the Baveno IV and Baveno II/III criteria in cirrhosis patients with variceal bleeding
    Dominique Thabut
    Service d Hepato Gastroenterologie, Hopital de la Pitie Salpetriere, APHP, UPMC, Paris, France
    Hepatology 61:1024-32. 2015
    ..65 for Baveno IV versus Baveno II/III and Baveno V criteria (P=0.001 for both). ABRI did not improve the diagnostic performance of the Baveno IV criteria. The Baveno IV, but not Baveno II/III, criteria independently predicted survival...
  30. doi Improved prognosis of septic shock in patients with cirrhosis: a multicenter study*
    Arnaud Galbois
    1AP HP, Hopital Saint Antoine, Service de Reanimation Medicale, Paris, France 2Université Pierre et Marie Curie UPMC, Univ Paris 06, Sorbonne Universités, Paris, France 3INSERM, UMR_S 938, CdR Saint Antoine, Paris, France 4AP HP, Hopital Ambroise Pare, Unité de Recherche Paris Ouest, Departement de sante publique, Boulogne, France 5Université Versailles Saint Quentin, UPRES EA 2506, Paris, France 6AP HP, Hopital Saint Antoine, Service d Hepatologie, Paris, France 7AP HP, Hopital de la Pitie Salpetriere, Service d Hepato Gastroenterologie, Paris, France 8INSERM, UMR_S 707, Paris, France
    Crit Care Med 42:1666-75. 2014
    ..To determine the evolution of the outcome of patients with cirrhosis and septic shock...
  31. ncbi The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease
    Dominique Thabut
    Department of Hepato Gastroenterology, Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 CNRS UMR 8149, Paris Cedex 13, France
    J Hepatol 44:1175-85. 2006
    ..The aim was to identify a panel of biomarkers (AshTest) for the diagnosis of alcoholic steato-hepatitis (ASH), in patients with chronic alcoholic liver disease...
  32. doi Assessment of adrenal function in cirrhotic patients: salivary cortisol should be preferred
    Arnaud Galbois
    Universite Pierre et Marie Curie, Service d Hepato Gastroenterologie, Hôpital de la Pitié Salpêtrière AP HP, Paris, France
    J Hepatol 52:839-45. 2010
    ....
  33. doi Hepatitis E infection in patients with severe alcoholic hepatitis: is there a place for systematic screening?
    Marika Rudler
    aAP HP, UPMC, Department of Hepatology and Gastroenterology bAP HP, UPMC, Department of Virology cAP HP, UPMC, Department of Anatomopathology, La Pitie Salpetriere Hospital, 47 80 Boulevard de l Hôpital, Assistance Publique Hopitaux de Paris, Pierre et Marie Curie University, Paris, France
    Eur J Gastroenterol Hepatol 27:1367-71. 2015
    ..6% of patients with severe alcoholic hepatitis (AH). However, validation of these preliminary results is lacking, as well as the impact of HEV infection on the 6-month survival...
  34. doi Noninvasive assessment of portal hypertension in patients with cirrhosis
    Dominique Thabut
    Institut National de la Santé et de la Recherche Médicale Unité 773, Centre de recherche Biomedicale Bichat Beaujon, Paris, France
    Hepatology 53:683-94. 2011
    ..Although most of these noninvasive methods effectively identify severe portal hypertension, methods for diagnosing moderate portal hypertension need to be developed; this shows that further investigation is needed in this field...
  35. doi Glycogen synthase kinase 3 involvement in the excessive proinflammatory response to LPS in patients with decompensated cirrhosis
    Nicolas Coant
    INSERM, U773, Centre de Recherche Biomedicale Bichat Beaujon CRB3, Paris and Clichy, France
    J Hepatol 55:784-93. 2011
    ..Thus, we investigated the role of GSK3 in LPS-induced cytokine production by peripheral blood mononuclear cells (PBMCs) or monocytes from patients with advanced cirrhosis and normal subjects...
  36. ncbi Cost of treatment of oesophageal variceal bleeding in patients with cirrhosis in France: results of a French survey
    Dominique Thabut
    Department of Hepatogastroenterology, Pitié Salpêtrière Hospital AP HP, Paris, France
    Eur J Gastroenterol Hepatol 19:679-86. 2007
    ..To estimate the costs to treat oesophageal variceal bleeding in patients with cirrhosis in France from a hospital perspective...
  37. pmc Invasive pulmonary aspergillosis in patients with decompensated cirrhosis: case series
    Hélène Prodanovic
    Assistance Publique Hopitaux de Paris, Service de Pneumologie et Reanimation, Groupe Hospitalier Pitie Salpetriere, Paris, France
    BMC Gastroenterol 7:2. 2007
    ..Liver failure has been suspected to be a risk factor for aspergillosis...
  38. doi Nonalcoholic fatty liver disease increases the risk of hepatocellular carcinoma in patients with alcohol-associated cirrhosis awaiting liver transplants
    Raluca Pais
    Service d Hepatogastroenterologie, Hopital Pitie Salpetriere, Paris, France
    Clin Gastroenterol Hepatol 13:992-9.e2. 2015
    ..We analyzed the prevalence and prognostic implications of metabolic risk factors (MRFs) such as overweight, diabetes, dyslipidemia, and hypertension in patients with alcohol-associated cirrhosis awaiting liver transplants...
  39. doi Prognosis of treated severe alcoholic hepatitis in patients with gastrointestinal bleeding
    Marika Rudler
    AP HP, UPMC, Department of Hepatogastroenterology, La Pitie Salpetriere Hospital, 47 80 Boulevard de l Hôpital, Assistance Publique Hopitaux de Paris, Pierre et Marie Curie University, 75013 Paris, France
    J Hepatol 62:816-21. 2015
    ....
  40. doi Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard
    Thierry Poynard
    Hepato Gastroenterology, APHP UPMC Liver Center, Paris, France
    J Hepatol 58:928-35. 2013
    ..The aim was to assess the applicability and performances of SWE for the diagnosis of fibrosis as compared with FibroTest (FT) and liver stiffness measurement (LSM) by transient elastography using two probes (TE-M and TE-XL)...
  41. ncbi Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis
    Jean Baptiste Nousbaum
    Services d Hépato Gastroentérologie de, Brest, U773, Centre de Recherche Biomedicale Bichat Beaujon CRB3, Hopital Beaujon, Clichy, France
    Hepatology 45:1275-81. 2007
    ..04). Using a threshold of 2+ for positivity of the reagent strip, sensitivity was 45.3% for the diagnosis of SBP, specificity was 99.2%, positive predictive value was 77.9%, and negative predictive value was 96.9%...
  42. ncbi Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors
    Francoise Imbert-Bismut
    Service of Biochemistry, hôpital La Pitié Salpêtrière, Paris, France
    Clin Chem Lab Med 42:323-33. 2004
    ..075+/-0.004 and 0.068+/-0.004, respectively. The low intra-laboratory and intra-patient variability in Fibrotest and Actitest results confirm Fibrotest and Actitest reliability...
  43. doi Ranking hepatologists: which Hirsch's h-index to prevent the "e-crise de foi-e"?
    Thierry Poynard
    UPMC, Service d Hepato Gastroenterologie, Paris Liver Center, Groupe Hospitalier Pitie Salpetriere, AP HP, 47 83, Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Clin Res Hepatol Gastroenterol 35:375-86. 2011
    ..The aim was to analyze the discordance rates in Hepatology between five h-I assessments from five databases: Scholar, Scopus, Web of Science (WoS), ScholarL restricted to "liver", and a specialty h-I HepaTop...
  44. pmc Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison
    Thierry Poynard
    Hepato Gastroenterology, APHP UPMC Liver Center, Paris, France
    PLoS ONE 11:e0163276. 2016
    ..The aims were to compare several criteria of applicability, and to assess inflammation and steatosis impact on elasticity values, two unmet needs...
  45. doi Prevalence of renal abnormalities in chronic HBV infection: the HARPE study
    Sabine Amet
    Service ICAR, Department of Nephrology, Hopital Pitie Salpetriere, Paris, France
    Liver Int 35:148-55. 2015
    ..The multicentric cross-sectional HARPE study evaluated the prevalence of kidney disease indicators, in chronic HBV surface antigen carriers patients (HBsAg+) with active or inactive infection...
  46. doi Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®)
    Thierry Poynard
    Assistance Publique Hopitaux de Paris AP HP, University Pierre Marie Curie UPMC, INSERM, UMR_S 938, Liver Center, Paris, France Electronic address
    J Hepatol 60:706-14. 2014
    ..1), esophageal varices (F4.2), and severe complications (F4.3): primary liver cancer, variceal bleeding, or decompensation (ascites, encephalopathy, or jaundice)...
  47. doi Erythromycin infusion or gastric lavage for upper gastrointestinal bleeding: a multicenter randomized controlled trial
    Dominique Pateron
    Emergency Department, Saint Antoine Hospital, Assistance Publique Hopitaux de Paris, Pierre et Marie Curie Paris 6 University, Paris, France
    Ann Emerg Med 57:582-9. 2011
    ..We determine whether in acute upper gastrointestinal bleeding the frequency of satisfactory stomach visualization was different after intravenous erythromycin, a nasogastric tube with gastric lavage, or both...
  48. doi FibroTest and Fibroscan performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate
    Thierry Poynard
    APHP UPMC Liver Center, 75013 Paris, France
    Clin Res Hepatol Gastroenterol 35:720-30. 2011
    ..Furthermore the performance of these biomarkers have not been assessed in "intention to diagnose" which takes into account the failures and non-reliable results...
  49. pmc Hirsch index and truth survival in clinical research
    Thierry Poynard
    University Pierre et Marie Curie Assistance Publique Hôpitaux de Paris Liver Center, Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    PLoS ONE 5:e12044. 2010
    ..We hypothesized that publications with a first author having a higher Hirsch' index value (h-I), which quantifies and predicts an individual's scientific research output, should have a longer half-life...
  50. doi Optimal nonsurgical management of peptic ulcer bleeding, including arterial embolization is associated with a mortality below 1%
    Marika Rudler
    UPMC, Department of Hepatogastroenterology, La Pitie Salpetriere Hospital, Pierre et Marie Curie University, Assistance Publique Hopitaux de Paris, 47 83, Boulevard de l Hopital, 75013 Paris, France
    Clin Res Hepatol Gastroenterol 37:64-71. 2013
    ..Arterial embolization of PUB has been shown efficient and safe in small retrospective series, but optimal medical treatment was not used...
  51. ncbi [What are the indications for treatment of acute hepatitis C?]
    Robert P Myers
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Paris
    Gastroenterol Clin Biol 26:B188-93. 2002
  52. pmc A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease
    Philippe Halfon
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, AP HP, Université Paris 6 et UPRESA 8067 CNRS Paris, 47 Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Comp Hepatol 1:3. 2002
    ..Standardized methods and assay calibration should be used and expression of alanine aminotransferase and gamma-glutamyl transpeptidase in multiples of the upper limit of reference values should not be employed...
  53. ncbi Modification in CSF specific gravity in acutely decompensated cirrhosis and acute on chronic liver failure independent of encephalopathy, evidences for an early blood-CSF barrier dysfunction in cirrhosis
    Nicolas Weiss
    Brain Liver Pitié Salpêtrière Study Group BLIPS, Hopital de la Pitie Salpetriere, and INSERM UMR_S 938, CdR Saint Antoine, Assistance Publique Hopitaux de Paris, Paris, France
    Metab Brain Dis . 2016
    ..This pattern is observed even in the absence of hepatic encephalopathy suggesting that blood-CSF barrier impairment is manifest even in absence of overt hepatic encephalopathy...
  54. doi Status epilepticus in patients with cirrhosis: How to avoid misdiagnosis in patients with hepatic encephalopathy
    Marika Rudler
    Brain Liver Pitié Salpêtrière Study Group BLIPS, Groupe hospitalier Pitié Salpêtrière Charles Foix, Paris, France Unité de Soins Intensifs d Hépatologie, Service d Hepato Gastroenterologie, Groupe hospitalier Pitié Salpêtrière Charles Foix, Assistance Publique Hopitaux de Paris, Paris, France Electronic address
    Seizure 45:192-197. 2016
    ..In this retrospective study, we therefore assessed the frequency of SE in patients with cirrhosis, evaluated the accuracy of diagnosis and determined rates of mortality...
  55. doi Portal myofibroblasts connect angiogenesis and fibrosis in liver
    Sara Lemoinne
    Sorbonne Universités, UPMC Univ Paris 06, INSERM, Centre de Recherche Saint Antoine CRSA and Institute of Cardiometabolism and Nutrition ICAN, F 75012, Paris, France
    Cell Tissue Res 365:583-9. 2016
    ....
  56. doi Portal myofibroblasts promote vascular remodeling underlying cirrhosis formation through the release of microparticles
    Sara Lemoinne
    Sorbonne Universités, UPMC Universite Paris 06, CDR Saint Antoine and Institute of Cardiometabolism and Nutrition ICAN, Paris, France INSERM, UMR_S 938, Paris, France
    Hepatology 61:1041-55. 2015
    ..Cholangiocytes potentiated the angiogenic properties of PMFs by increasing VEGFA expression and microparticle shedding in these cells...
  57. ncbi Polymorphonuclear neutrophils are a source of hepatocyte growth factor in patients with severe alcoholic hepatitis
    Julien Taieb
    Hepatology Department, Pitie Salpetriere Hospital, 47, Boulevard de l Hopital, 75651, Cedex 13, Paris, France
    J Hepatol 36:342-8. 2002
    ..As AH is accompanied by inflammation, neutrophilia and polymorphonuclear neutrophil (PMN) infiltration of the liver, we postulated that PMN could be a source of HGF in such patients...
  58. doi Improvement in the prognosis of cirrhotic patients admitted to an intensive care unit, a retrospective study
    Arnaud Galbois
    AP HP, Saint Antoine Hospital, Medical Intensive Care Unit, 184 rue du Faubourg, Saint Antoine, Paris Cedex 12, France
    Eur J Gastroenterol Hepatol 24:897-904. 2012
    ..To examine how the outcomes of cirrhotic patients admitted to an ICU have changed over time...
  59. doi Early TIPS with covered stents in high-risk patients with cirrhosis presenting with variceal bleeding: are we ready to dive into the deep end of the pool?
    Dominique Thabut
    Universite Pierre et Marie Curie, Service d Hepato Gastroenterologie, Hôpital de la Pitié Salpêtrière AP HP, Paris, France
    J Hepatol 55:1148-9. 2011
    ..This study evaluated the earlier use of TIPS in such patients...
  60. ncbi Recombinant activated factor VII in chronic liver diseases: should we be afraid of thromboembolic events?
    Dominique Thabut
    Universite Pierre et Marie Curie, Service d Hepato Gastroenterologie, Hôpital de la Pitié Salpêtrière AP HP, Paris, France
    J Hepatol 55:483-5. 2011
  61. doi Cerebrospinal fluid metabolomics highlights dysregulation of energy metabolism in overt hepatic encephalopathy
    Nicolas Weiss
    Brain Liver Pitié Salpêtrière BLIPS Study Group, Groupement Hospitalier Pitié Salpêtrière Charles Foix, Paris, France Unité de réanimation neurologique, Fédération de neurologie 1, Pôle des maladies du système nerveux, Groupement Hospitalier Pitié Salpêtrière Charles Foix, Assistance Publique Hôpitaux de Paris et Institut de neurosciences translationnelles IHU A ICM, Paris, France
    J Hepatol 65:1120-1130. 2016
    ..However, the pathophysiological mechanisms of HE remain poorly understood. In this context, metabolomics was used to highlight dysfunction of metabolic pathways in cerebrospinal fluid (CSF) samples of patients suffering from HE...
  62. doi FOUR score, a reliable score for assessing overt hepatic encephalopathy in cirrhotic patients
    Sarah Mouri
    Brain Liver Pitié Salpêtrière Study Group BLIPS, Paris, France
    Neurocrit Care 22:251-7. 2015
    ..The scale covers eye and motor responses, brainstem reflexes and breathing patterns and is the most validated coma scale...
  63. doi The emerging roles of microvesicles in liver diseases
    Sara Lemoinne
    INSERM, UMRS 938, Centre de Recherche Saint Antoine, Sorbonne Universités, Universite Pierre et Marie Curie Paris 6, 27 rue Chaligny, 75571 Paris, France
    Nat Rev Gastroenterol Hepatol 11:350-61. 2014
    ..Several results also suggest that MVs have a role in hepatocellular carcinoma. Although MVs represent promising biomarkers in patients with liver disease, methods of isolation and subsequent analysis must be standardized. ..
  64. doi Kinetic profiles and management of hepatitis B virus reactivation in patients with immune-mediated inflammatory diseases
    Nina Droz
    Universite Paris Descartes, AP HP, Hopital Cochin, Paris, France
    Arthritis Care Res (Hoboken) 65:1504-14. 2013
    ..We aimed to describe HBV reactivation in patients receiving treatment for immune-mediated inflammatory diseases (IMIDs) and to evaluate a predefined algorithm for its prevention...
  65. ncbi [Gastrointestinal hemorrhage. How to prevent rebleeding: role of pharmacological and endoscopic treatments]
    Dominique Thabut
    Service d Hepato Gastroenterologie, Hopital de la Pitie Salpetriere, 47 83 boulevard de l Hopital, 75013, Paris
    Gastroenterol Clin Biol 28:B73-82. 2004
  66. doi [Medical specialty choice: what impact of teaching? Results of a survey of two medical schools]
    Sonia Gaucher
    Universite Paris Descartes, Faculte de Medecine, Sorbonne Paris Cité, and AP HP, Hopital Pitie Salpetriere, Service d Hepato gastro enterologie, 75004 Paris, France
    Presse Med 42:e89-95. 2013
    ..Determinants of career choice are numerous. The impact of teaching has not yet been reported...
  67. ncbi The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C
    Sophie Le Calvez
    Hepatology 39:862-3; author reply 863. 2004
  68. ncbi Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy?
    Thierry Poynard
    Gastroenterology 128:1146-8; author reply 1148. 2005
  69. ncbi Effects of ursodeoxycholic acid (ursodiol) treatment on chronic viral hepatitis in heart transplant patients: results of a prospective, double-blind, placebo-randomized study
    Jean Francois Cadranel
    Unité d Hépatologie, Centre Hospitalier Laennec, BP 72, 60109 Creil Cedex, France
    Transplantation 75:977-82. 2003
    ..We used a double-blind randomized controlled trial to evaluate the effect of ursodiol in heart transplant patients with chronic viral hepatitis...
  70. ncbi Noninvasive prediction of fibrosis in patients with chronic hepatitis C
    Dominique Thabut
    Hepatology 37:1220-1; author reply 1221. 2003
  71. ncbi Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease
    Sylvie Naveau
    Department of Hepato Gastroenterology, Hopital Antoine Beclere, Clamart, France
    Clin Gastroenterol Hepatol 3:167-74. 2005
    ..The aim of this study was to determine the diagnostic use of noninvasive markers of fibrosis in patients with chronic alcoholic liver disease...
  72. ncbi Anti-tumor necrosis factor-alpha therapy in severe alcoholic hepatitis: are large randomized trials still possible?
    Thierry Poynard
    J Hepatol 38:518-20. 2003
  73. ncbi Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial
    Jaime Bosch
    Hospital Clinic, Liver Unit, Barcelona, Spain
    Gastroenterology 127:1123-30. 2004
    ..This trial aimed to determine efficacy and safety of rFVIIa in cirrhotic patients with variceal and nonvariceal UGIB...
  74. ncbi Screening for esophageal varices: Endoscopy, other tools, or endoscopy and other tools?
    Dominique Thabut
    Hepatology 47:1434-6. 2008
  75. ncbi Diagnostic value of FibroTest with normal serum aminotransferases
    Thierry Poynard
    Hepatology 43:374-5; author reply 375-6. 2006
  76. doi Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial
    Jaime Bosch
    Hepatic Hemodynamic Laboratory, Hospital Clinic and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, University of Barcelona, Spain
    Hepatology 47:1604-14. 2008
    ..A marked heterogeneity in the failure rate in all treatment groups was observed across participating centers. Adverse events, including overall thromboembolic events, were comparable between groups...
  77. doi Reproducibility of non-invasive fibrosis biomarkers, FibroMeter and FibroTest, could be improved by respecting the analytical standardizations
    Mona Munteanu
    Clin Biochem 41:1113-4. 2008